Composite Human Antibody™: Advanced Antibody Humanization

The immunogenicity of therapeutic antibodies has long been a major issue in the clinic and the development of anti-therapeutic antibody responses in patients limits the efficacy of these therapeutics. This challenge has been reduced through the development of humanization and fully-human antibody engineering technologies. Despite these improvements, clinical studies have shown that many humanized and fully-human antibodies are still immunogenic in patients.

Abzena developed our ground-breaking Composite Human Antibody™ technology to create fully-humanized antibodies. These retain the binding affinity and specificity of the starting monoclonal antibody. They are also devoid of CD4+ T cell epitopes, thereby avoiding undesirable immunogenicity in patients.